18 results on '"Kim, Sung Hyun"'
Search Results
2. Preoperative Fistula Risk Prediction Using Computed Tomography Image Before Pancreatoduodenectomy
- Author
-
Kim, Sung Hyun, Kim, Seung-seob, Hwang, Ho Kyoung, Kang, Chang Moo, Choi, Jin-Young, Kim, Kyung Sik, and Kim, Hyoung-Il
- Published
- 2023
- Full Text
- View/download PDF
3. Comparison of Survival Outcomes between Radical Antegrade Modular Pancreatosplenectomy and Conventional Distal Pancreatosplenectomy for Pancreatic Body and Tail Cancer: Korean Multicenter Propensity Score Match Analysis.
- Author
-
Kwon, Jaewoo, Lee, Huisong, Kim, Hongbeom, Kim, Sung Hyun, Yang, Jae Do, Lee, Woohyung, Lee, Jun Suh, Shin, Sang Hyun, and Kim, Hee Joon
- Subjects
LYMPH nodes ,T-test (Statistics) ,FISHER exact test ,EVALUATION of medical care ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,MULTIVARIATE analysis ,MANN Whitney U Test ,PANCREATIC tumors ,KAPLAN-Meier estimator ,LOG-rank test ,SPLENECTOMY ,PANCREATECTOMY ,RESEARCH ,STATISTICS ,COMPARATIVE studies ,PROGRESSION-free survival ,PROGNOSIS ,DATA analysis software ,PROPORTIONAL hazards models - Abstract
Simple Summary: Our study aimed to compare the operative and survival outcomes between radical antegrade modular pancreatosplenectomy (RAMPS) and conventional distal pancreatosplenctomy (cDPS), and identify prognostic factors for left-sided pancreatic cancer. We performed a retrospective propensity score match (PSM) analysis from 333 patients who underwent RAMPS or cDPS for left-sided pancreatic cancer. After PSM, 99 cohorts were matched in each group. We compared survival and operative outcomes and assessed prognostic factors. R0 resection rate was similar between both groups, and R1 resection rate was a significant prognostic factor. RAMPS was found to be safe, feasible, and to improve the number of retrieved lymph nodes. However, when R0 resection was similar in both groups, RAMPS was not associated with improved survival. Adjuvant treatment was a significant independent prognostic factor for overall and disease-free survival, but operation type was not. (1) Background: The aim of this study was to compare the survival benefit of radical antegrade modular pancreatosplenectomy (RAMPS) with conventional distal pancreatosplenectomy (cDPS) in left-sided pancreatic cancer. (2) Methods: A retrospective propensity score matching (PSM) analysis was conducted on 333 patients who underwent RAMPS or cDPS for left-sided pancreatic cancer at four tertiary cancer centers. The study assessed prognostic factors and compared survival and operative outcomes. (3) Results: After PSM, 99 patients were matched in each group. RAMPS resulted in a higher retrieved lymph node count than cDPS (15.0 vs. 10.0, p < 0.001). No significant differences were observed between the two groups in terms of R0 resection rate, blood loss, hospital stay, or morbidity. The 5-year overall survival rate was similar in both groups (cDPS vs. RAMPS, 44.4% vs. 45.2%, p = 0.853), and disease-free survival was also comparable. Multivariate analysis revealed that ASA score, preoperative CA19-9, histologic differentiation, R1 resection, adjuvant treatment, and lymphovascular invasion were significant prognostic factors for overall survival. Preoperative CA19-9, histologic differentiation, T-stage, adjuvant treatment, and lymphovascular invasion were independent significant prognostic factors for disease-free survival. (4) Conclusions: Although RAMPS resulted in a higher retrieved lymph node count, survival outcomes were not different between the two groups. RAMPS was a surgical option to achieve R0 resection rather than a standard procedure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study
- Author
-
Oh, Sukjoong, Koo, Dong Hoe, Kwon, Min-Jung, Kim, Kihyun, Suh, Cheolwon, Min, Chang-Ki, Yoon, Sung-Soo, Shin, Ho-Jin, Jo, Deog-Yeon, Kwak, Jae-Yong, Kim, Jin Seok, Sohn, Sang Kyun, Joo, Young-Don, Eom, Hyeon-Seok, Kim, Sung-Hyun, Kim, Yang Soo, Kim, ChulSoo, Mun, Yeung-Chul, Kim, Hawk, Lee, Dong Soon, Lee, Jae Hoon, and the Korean Multiple Myeloma Working Party (KMMWP)
- Published
- 2014
- Full Text
- View/download PDF
5. Clinical characteristics and prognostic factors of acquired haemophilia A in Korea.
- Author
-
Hyun, Shin Young, Shin, Ho‐Jin, Yoon, Sung‐Soo, Moon, Joon Ho, Han, Jae Joon, Yang, Deok‐Hwan, Lee, Won Sik, Bang, Soo‐Mee, Yhim, Ho‐Young, Kim, Sung‐Hyun, Oh, Doyeun, Do, Young Rok, Park, Yong, Choi, Chul Won, Lee, Je‐Hwan, Jang, Ji Eun, Kim, Soo‐Jeong, Hwang, Doh Yu, and Kim, Jin Seok
- Subjects
PROGNOSIS ,BLOOD coagulation factor VIII antibodies ,OVERALL survival ,HEMOPHILIA ,LOGISTIC regression analysis - Abstract
Introduction: Acquired haemophilia A (AHA) treatment involves the haemostatic treatment for acute haemorrhage and immunosuppressive therapy (IST) to eradicate FVIII inhibitory antibodies. Aim: We assessed the clinical features of AHA and analysed treatment outcomes in Korea. We further identified prognostic factors affecting treatment outcomes. Methods: Medical records of 55 patients with AHA from 18 institutions were reviewed retrospectively. Logistic and Cox regression analyses were performed to elucidate clinical factors affecting the achievement of complete remission (CR). The primary endpoint was time to CR after IST, and secondary endpoints were time to haemostasis, the achievement of CR, and overall survival (OS). Results: Among the 55 patients, 50 (91%) had bleeding symptoms. Bleeding was severe in 74% of patients. Thirty‐six (72%) patients received haemostatic therapy. Of the 42 patients who received IST, 23 (52%) received steroid alone, with a 52% response rate, and 10 (25%) received a combination of steroid and cyclophosphamide, with an 83% response rate. Five (16%) patients relapsed after a median duration of 220 days. There were eight deaths. In the Cox regression analysis, the FVIII inhibitor titre ≥ 20 BU/mL was the only significant prognostic factor affecting time to CR and haemostasis. No significant difference was observed in OS based on the inhibitor titre. Conclusion: The present study demonstrated the demographic data of AHA in Korea and showed that FVIII inhibitory antibody titre was a predictor of time to achieve CR after IST. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Recommended Minimal Number of Harvested Lymph Nodes for Intrahepatic Cholangiocarcinoma.
- Author
-
Kim, Sung Hyun, Han, Dai Hoon, Choi, Gi Hong, Choi, Jin Sub, and Kim, Kyung Sik
- Subjects
- *
LYMPH nodes , *CHOLANGIOCARCINOMA , *LYMPHADENECTOMY , *RETROSPECTIVE studies , *PROGNOSIS , *TUMOR classification , *SURGICAL excision , *LYMPH node surgery , *PROBABILITY theory ,BILE duct tumors - Abstract
Background: Lymph node (LN) metastasis is one factor indicating a poor prognosis after radical surgery for intrahepatic cholangiocarcinoma (ICC). Although several guidelines have recommended that LN dissection be strongly considered at the time of ICC surgery, no clear evidence regarding the appropriate number of harvested LNs has been established. Thus, we aimed to identify the minimum number of harvested LNs required for ICC by using a Bayesian Weibull model.Methods: Data from 142 patients who underwent radical hepatectomy (R0) for ICC from January 2000 to December 2018 were retrospectively reviewed. A Bayesian Weibull model was developed to analyze the effect of number of harvested LNs on survival of patients without (N0; n = 71) and with (N1; n = 71) metastatic nodes. We also compared the percentage of N1 patients (i.e., the N1 rate) in each of the five subgroups categorized according to the number of harvested LNs (1-4, 5-8, 9-12, 13-16, and ≥ 17).Results: In patients with 5 or more harvested LNs, the hazard ratio (HR) for LN metastasis was above the reference line (the HR with 5 harvested LNs, 1.95 (1.09-3.45)). The N1 rate of the 1-4 harvested LNs subgroup was lower than that of the other subgroups (e.g., 1-4 vs. 5-8; 16.1% vs. 39.4%, p = 0.014).Conclusion: Our results suggest that at least 5 LNs should be harvested in patients who undergo radical surgery for ICC to promote accurate staging. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
- Author
-
Jo, Jae-Cheol, Lee, Ho Sup, Kim, Kihyun, Lee, Je-Jung, Yoon, Sung-Soo, Bang, Soo-Mee, Kim, Jin Seok, Eom, Hyeon-Seok, Yoon, Dok Hyun, Lee, Yoojin, Shin, Ho-Jin, Park, Yong, Lee, Won Sik, Do, Young Rok, Mun, Yeung-Chul, Lee, Mark Hong, Kim, Hyo Jung, Kim, Sung-Hyun, Kim, Min Kyoung, and Lim, Sung-Nam
- Subjects
MULTIPLE myeloma ,DEXAMETHASONE ,UNIVERSITY hospitals ,COMORBIDITY ,MULTIVARIATE analysis ,RESEARCH ,RESEARCH methodology ,ANTINEOPLASTIC agents ,PROGNOSIS ,EVALUATION research ,MEDICAL cooperation ,DISEASE relapse ,COMPARATIVE studies - Abstract
Although lenalidomide plus dexamethasone (RD) is a therapeutic option for relapsed/refractory multiple myeloma (RRMM), limited real-world clinical data exist. The purpose of this study was to estimate efficacy and safety of RD in RRMM patients of the clinical practice. Data from patients at 25 university hospitals in South Korea between October 2009 and December 2016 were collected retrospectively. We report the effectiveness and safety of RD in 546 RRMM patients in routine clinical practice in South Korea. Patients (median age, 65 years) typically received median 7 cycles of RD, and 184 (33.7%) patients were treated with 10 or more cycles of RD. Patients with renal impairment (CLCr < 40 mL/min; 10.4%), comorbid conditions (≥ 2; 12.0%), and poor performance status (≥ 2; 25.1%) were included. The overall response rate was 64.2%: complete response (13.1%), very good partial response (VGPR 19.9%). With median follow-up duration of 18.6 months, median PFS and OS were 11.2 months and 25.2 months, respectively. In multivariate analysis, less than 2 comorbid conditions, normal LDH, failed one chemotherapy prior to RD, and ≥ 10 cycles of RD therapy had significantly prolonged PFS (P = 0.007, P = 0.011, P = 0.007, and P < 0.001, respectively). Adverse events were acceptable. RD is effective and safe in real-life clinical practice, including patients with comorbidities. RD is an effective and safe treatment in a real clinical setting which includes patients with comorbidities. Early and continual use of RD treatment may improve RRMM survival outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study.
- Author
-
Kim, Sung Hyun, Lee, Min Jung, Hwang, Ho Kyung, Lee, Sung Hwan, Kim, Hoguen, Paik, Young-Ki, and Kang, Chang Moo
- Subjects
- *
PANCREATIC cancer , *PLASMA potentials , *CANCER relapse , *PILOT projects , *TUMOR markers - Abstract
BACKGROUND: For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. OBJECTIVE: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients. METHODS: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p : 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p : 0.048). CONCLUSION: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
- Author
-
Jung, Sung-Hoon, Yang, Deok-Hwan, Kim, Sung-Hyun, Lee, Ji-Hyun, Sohn, Sang Kyun, Song, Ik-Chan, Lee, Hong-ghi, Cheong, Jung-Won, Choi, Yunsuk, Shin, Ho-Jin, Lee, Se-ryeon, Lee, Seok, Yoon, Jae-Ho, Lee, Hyewon, Bang, Soo-Mee, Koh, Youngil, Park, Silvia, Kim, Dae Sik, and Yhim, Ho-Young
- Subjects
LYMPHOBLASTIC leukemia treatment ,STEM cell transplantation ,ASIANS ,CLINICAL trials ,COMPARATIVE studies ,HOMOGRAFTS ,IMMUNOGLOBULINS ,LYMPHOBLASTIC leukemia ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,EVALUATION research - Abstract
Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1-4). Among the 49 evaluable patients, 22 (44.9%) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4%. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
- Author
-
Park, Silvia, Choi, Hangseok, Kim, Hee Je, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Kim, Sung-Hyun, Mun, Yeung-Chul, Jung, Chul Won, and Kim, Dennis (Dong Hwan)
- Subjects
ACUTE myeloid leukemia treatment ,ACUTE myeloid leukemia diagnosis ,STEM cell transplantation ,ALLELES ,BIOLOGICAL models ,DRUG therapy ,COMBINED modality therapy ,GENES ,GENETIC polymorphisms ,LONGITUDINAL method ,MORTALITY ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,ACUTE myeloid leukemia ,SEQUENCE analysis - Abstract
The present study attempted to build a single nucleotide polymorphism (SNP)-based risk model for predicting overall survival (OS) and event-free survival (EFS) in patients with core binding factor acute myeloid leukemia (CBF-AML). Adopting genome-wide SNP array using Affymetrix SNP array 6.0, we analyzed 868,157 SNPs with respect to OS and EFS in 104 patients with CBF-AML. Significant SNPs were identified from single SNP analysis. The risk model was constructed with incorporation of six SNPs and three clinical factors (age, c-kit exon 17 mutation, and LDH) for OS and six SNPs and three clinical factors (age, WBC, and LDH) for EFS. The model was further defined into low- and high-risk groups based on risk scores. The median age was 39 years, and the subgroup of t(8;21) and inv(16) or t(16;16) was assessed in 68 (65.4%) and 36 patients (34.6%). Finally, six SNPs per each OS (rs4353685, rs4908185, rs7709207, rs12034, rs1554844, and rs17241868) and EFS (rs13385610, rs11210617, rs11169282, rs7709207, rs4438401, and rs16894846) were incorporated into the risk model. OS was significantly different in favor of the low risk group (80.4 ± 8.4%) compared to the high-risk group (22.0 ± 7.3% at 3 years; p = 8.75 × 10- 13; HR 8.67). For EFS, there was also a significant difference between the low- (75.0 ± 5.8%) versus high-risk group (17.1 ± 6.3% at 3 years; p = 5.95 × 10- 13; HR 7.67). A genome-wide SNP-based risk model can stratify CBF-AML patients according to their OS and EFS in 104 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea.
- Author
-
Shin, Junghoon, Koh, Youngil, Yoon, Seo Hyun, Cho, Joo‐Youn, Kim, Dae‐Young, Lee, Kyoo‐Hyung, Kim, Hyeong‐Joon, Ahn, Jae‐Sook, Kim, Yeo‐Kyeoung, Park, Jinny, Sohn, Sang‐Kyun, Moon, Joon Ho, Lee, Yoo Jin, Yoon, Seonghae, Lee, Jeong‐Ok, Cheong, June‐Won, Kim, Kyoung Ha, Kim, Sung‐Hyun, Kim, Hoon‐Gu, and Kim, Hawk
- Subjects
NILOTINIB ,CHRONIC myeloid leukemia ,CHROMOSOMES ,ADVERSE health care events ,CONFIDENCE intervals - Abstract
Abstract: Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year efficacy and safety of nilotinib and their relationships with plasma nilotinib concentrations (PNCs). In this open‐label, multi‐institutional phase 4 study, 110 Philadelphia chromosome‐positive CML‐CP patients were treated with nilotinib at a starting dose of 300 mg twice daily. Molecular responses (MRs) and AEs were monitored for up to 24 months. The 24‐month cumulative MR
4.5 rate was evaluated as the primary endpoint. Plasma samples were collected from 94 patients to determine PNCs, and the per‐patient mean was used to categorize them into four mean PNC (MPNC) groups. Cumulative MR rates and safety were compared between groups. With a median follow‐up of 22.2 months, the 24‐month cumulative MR4.5 rate was 56.2% (95% confidence interval, 44.0%–8.3%), and the median time to MR4.5 was 23.3 months. There were no significant differences in the cumulative rates of major molecular response, MR4 , and MR4.5 between MPNC groups. One patient died due to acute viral hepatitis, and two developed hematological or cytogenetic relapse, while no progression to accelerated or blast phase was observed. Safety results were consistent with previous studies with no new safety signal identified. Across the MPNC groups, there was no significant linear trend in the frequency of AEs. Nilotinib is highly effective for the treatment of CML‐CP with manageable AEs. The measurement of PNC has no predictive value for patient outcomes and is thus not found to be clinically useful. This study is registered with clinicaltrials.gov, Number NCT03332511. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
12. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
- Author
-
Ahn, Jae-Sook, Kim, Jae-Young, Kim, Hyeoung-Joon, Kim, Yeo-Kyeoung, Lee, Seung-Shin, Jung, Sung-Hoon, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Nan, Choi, Seung, Minden, Mark, Jung, Chul, Jang, Jun-Ho, Kim, Hee, Moon, Joon, Sohn, Sang, Won, Jong-Ho, Kim, Sung-Hyun, Kim, Dennis, and Kim, Nan Young
- Subjects
MYELOID leukemia ,KARYOTYPES ,GENETIC mutation ,STEM cell transplantation ,CARRIER proteins ,PROGNOSIS ,ACUTE myeloid leukemia treatment ,ACUTE myeloid leukemia diagnosis ,CHROMOSOMES ,COMPARATIVE studies ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,EVALUATION research ,ACUTE myeloid leukemia ,TREATMENT effectiveness - Abstract
Normal karyotype acute myeloid leukemia (NK-AML) with CCAAT/enhancer binding protein α (CEBPA) mutations is known to have a more favorable prognosis. However, direct comparison of the clinical significance according to consolidation therapy has not been widely performed in patients with NK-AML. A total of 404 patients with NK-AML who received intensive induction chemotherapy were included in the present study. Diagnostic samples from the patients were evaluated for CEBPA mutations by direct sequencing. CEBPA single (sm) or double mutation (dm) was observed in 27 (6.7 %) and 51 (12.6 %) patients, respectively. CEBPA (dm) was associated with GATA2 (mut), and it was less frequently associated with FLT3-ITD(pos), NPM1 (mut), and DNMT3A (mut) in comparison with CEBPA (wild) or CEBPA (sm) (all p values <0.05). On multivariate analysis, CEBPA (dm) (p = 0.007, OR 39.593) was an independent risk factor for achievement of complete remission (CR). With a median follow-up of 40.1 months, CEBPA (dm) showed a favorable overall survival (OS), event-free survival (EFS), and lower relapse incidence (RI) in comparison with CEBPA (wild) (all p values <0.005). Comparison of clinical outcome analyses (consolidation chemotherapy vs. allogeneic hematopoietic cell transplantation (HCT)) demonstrated the role of consolidation treatment in patients with CEBPA (dm). Allogeneic HCT was associated with lower EFS and RI and a trend of higher non-relapse mortality. However, there was no statistically significant difference in OS. In conclusion, CEBPA (dm) was associated with other molecular mutations. Consolidation chemotherapy alone may overcome higher relapse rates by reducing the treatment mortality and increasing survival after relapse events in patients with CEBPA (dm) in NK-AML. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.
- Author
-
Hwang, In, Kang, Jung, Oh, Sung, Lee, Suee, Kim, Sung-Hyun, Song, Ki-Hoon, Son, Choonhee, Park, Min, Kang, Myung, Kim, Hoon, Lee, Jeeyun, Park, Young, Sun, Jong, Kim, Hyun, Kim, Chan, Yi, Seong, Jang, Joung-Soon, Park, Keunchil, Kim, Hyo-Jin, and Hwang, In Gyu
- Subjects
ERLOTINIB ,SKIN infections ,TREATMENT effectiveness ,PROTEIN-tyrosine kinase inhibitors ,EPIDERMAL growth factor receptors ,THERAPEUTICS ,ANTINEOPLASTIC agents ,CLINICAL trials ,COMPARATIVE studies ,DERMATOLOGIC agents ,DRUG eruptions ,EPIDERMAL growth factor ,LUNG cancer ,LUNG tumors ,RESEARCH methodology ,MEDICAL cooperation ,OINTMENTS ,PANCREATIC tumors ,PROGNOSIS ,RESEARCH ,EVALUATION research ,DISEASE progression ,PROTEIN kinase inhibitors - Abstract
Purpose: The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). In the present study, we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs).Methods: This was an open-label, non-comparative, multicenter, phase II trial. The patients included those diagnosed with NSCLC or PC who were treated with erlotinib. The effectiveness of the ointment was defined as follows: (1) grade 2, 3, or 4 ERSEs downgraded to ≤ grade 1 or (2) grade 3 or 4 ERSEs downgraded to grade 2 and persisted for at least 2 weeks.Results: Fifty-two patients from seven institutes in Korea were enrolled with informed consent. The final assessment included 46 patients (30 males, 16 females). According to the definition of effectiveness, the EGF ointment was effective in 36 (69.2%) intention to treat patients. There were no statistically significant differences in the effectiveness of the EGF ointment by gender (p = 0.465), age (p = 0.547), tumor type (p = 0.085), erlotinib dosage (p = 0.117), and number of prior chemotherapy sessions (p = 0.547). The grading for the average National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) rating of rash/acne and itching improved from 2.02 ± 0.83 to 1.13 ± 0.89 and 1.52 ± 0.84 to 0.67 ± 0.90, respectively (p < 0.001). The most common reason for discontinuing the study was progression of cancer (37%).Conclusions: Based on the results, the EGF ointment is effective for ERSEs, regardless of gender, age, type of tumor, and dosage of erlotinib. The EGF ointment evenly improved all kinds of symptoms of ERSEs.Clinical Trial Registration No: ClinicalTrials.gov identifier: NCT01593995. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
- Author
-
Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim, Hyo-Jin Kim, Lee, Suee, Oh, Sung Yong, Kim, Sung Hyun, Lee, Ji Hyun, Kim, Min Chan, Kim, Ki Han, and Kim, Hyo-Jin
- Subjects
NEUTROPHILS ,LYMPHOCYTES ,OXALIPLATIN ,CANCER patients ,BIOMARKERS ,CANCER chemotherapy ,MULTIVARIATE analysis ,DIAGNOSIS ,ADENOCARCINOMA ,STOMACH tumors ,FOLINIC acid ,RESEARCH ,BLOOD platelets ,RESEARCH methodology ,PROGNOSIS ,ANTINEOPLASTIC agents ,MEDICAL cooperation ,EVALUATION research ,ORGANOPLATINUM compounds ,FLUOROURACIL ,COMPARATIVE studies ,LEUKOCYTE count ,KAPLAN-Meier estimator ,PROPORTIONAL hazards models - Abstract
Background: Several inflammatory response materials could be used for prediction of prognosis of cancer patients. The neutrophil lymphocyte ratio (NLR), and the platelet lymphocyte ratio (PLR) have been introduced for prognostic scoring system in various cancers. The objective of this study was to determine whether the NLR or the PLR would predict the clinical outcomes in advanced gastric cancer patients treated with oxaliplatin/ 5-fluorouracil (FOLFOX).Methods: The study population consisted of 174 advanced gastric cancer patients. Patients were treated with 85 mg/m2 of oxaliplatin as a 2-h infusion at day 1 plus 20 mg/m2 of leucovorin over 10 min, followed by 5-FU bolus 400 mg/m2 and 22-h continuous infusion of 600 mg/m2 at days 1-2. Treatment was repeated in 2-week intervals. The NLR and PLR were calculated from complete blood counts in laboratory test before and after first cycle of chemotherapy.Results: NLR was a useful prognostic biomarker for predicting inferior overall survival (OS) (p = 0.005), but was not associated with progression free survival (PFS) (p = 0.461). The normalization of NLR after one cycle of chemotherapy was found to be in association with significant improvement in PFS (5.3 months vs. 2.4 months, p < 0.001), and OS (11.9 months vs. 4.6 months, p < 0.001). The normalization of PLR was also associated with longer PFS (5.6 months vs. 3.4 months, p = 0.006), and OS (16.9 months vs. 10.9 months, p = 0.002). In multivariate analysis, changes in NLR were associated with PFS (Hazard ratio (HR): 2.297, 95% confidence interval (CI): 1.429-3.693, p = 0.001). The NLR, (HR: 0.245, 95% CI: 0.092-0.633, p = 0.004), PLR (HR: 0.347, 95% CI: 0.142-0.847, p = 0.020), changes in NLR (HR: 2.468, 95% CI: 1.567-3.886, p < 0.001), and changes in PLR (HR: 1.473, 95% CI: 1.038-2.090, p = 0.030) were independent prognostic markers for OS.Conclusion: This study demonstrates that NLR, PLR, and changes in NLR or PLR are independent prognostic factor for OS in patients with advanced gastric cancer treated with chemotherapy. These specific factors may also help in identifying the patients, who are more sensitive to FOLFOX regimen. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
15. Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy.
- Author
-
Oh, Sung Yong, Kwon, Hyuk-Chan, Kim, Sung Hyun, Lee, Suee, Lee, Ji Hyun, Graves, Christian A., Camphausen, Kevin, and Kim, Hyo-Jin
- Subjects
STOMACH cancer ,SERUM ,VASCULAR endothelial growth factors ,SOMATOMEDIN C ,CANCER chemotherapy ,CANCER invasiveness ,CELL proliferation ,PROGNOSIS - Abstract
Background: Tumor vascular endothelial growth factor (VEGF) is a key angiogenic factor and may have an impact on tumor progression and response to chemotherapy. The insulin-like growth factor (IGF) system is related to cell proliferation and tumor growth. However, there is limited available data regarding the clinical and prognostic significance of VEGF or IGF-1 in advanced gastric cancer. The aim of this study was to evaluate the prognostic significance of serum VEGF and IGF-1 levels in advanced gastric cancer patients who were treated with oxaliplatin/5-fluorouracil (FOLFOX). Methods: The study population consisted of 100 advanced gastric cancer patients (median age 56 years). Patients were treated with oxaliplatin 85 mg/m
2 as a 2-hour infusion on day 1 plus leucovorin 20 mg/m2 over 10 min, followed by a 5-fluorouracil (5-FU) bolus 400 mg/m2 and 22 h of continuous infusion of 600 mg/m2 on days 1-2. Treatment was repeated in 2-week intervals. The levels of serum VEGF and IGF-1 were measured using enzyme-linked immunoassays. Results: There was a significant correlation between the serum level of VEGF and Lauren's classification (p = 0.030) and previous operations (p = 0.010). IGF-1 was associated with the number of metastases (p = 0.012). The median level of serum VEGF was decreased after FOLFOX chemotherapy (p = 0.034). However, none of the measured serum markers were significantly correlated with response. In univariate analysis, overall survival (p < 0.001) was significantly shorter in patients with high serum levels of VEGF. Multivariate analysis revealed that VEGF was an independent factor for overall survival (HR 2.221; 95% CI 1.377-3.583, p = 0.001). Furthermore, IGF-1 had no significant influence on the clinical outcome. Conclusion: A high level of serum VEGF is an independent prognostic factor in patients with advanced gastric cancer treated with chemotherapy. This may help to identify the patients who are more sensitive to the FOLFOX regimen. Copyright © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
16. Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome
- Author
-
Kim, Sung-Hyun, Lee, Ji Hyun, Choi, Jimin, Kwon, Kyung A, Lee, Suee, Oh, Sung Yong, Kwon, Hyuk-Chan, Han, Jin-Yeong, and Kim, Hyo-Jin
- Subjects
- *
MYELODYSPLASTIC syndromes treatment , *RETROSPECTIVE studies , *LEUKEMIA treatment , *LEUCOCYTOSIS , *DYSPLASIA , *BONE marrow diseases , *MEDICAL care - Abstract
Abstract: Background: The aim of this study was to improve the predictive power of the WHO classification-based prognostic scoring system (WPSS) by including age in patients with the myelodysplastic syndrome (MDS). Patients and methods: 136 Korean patients with de novo MDS between 1995 and 2008 were evaluated retrospectively. All patients were reclassified according to WHO criteria. 114 patients were included in the final analysis. An individualized age-adapted scoring system was developed to improve the accuracy of prognosis of the WPSS. Results: The WPSS was significantly associated with the prediction of survival and the leukemia-free survival. While the risk of a patient with the WPSS was best represented by the values 0 (very low), +1 (low), +2 (intermediate), +3 (high), and +4 (very high), these values were found to vary between −1.0 and 4.2 in the same patients when age was included as a factor. The WPSS may vary according to age, <55 or ≥55 years. The estimated difference in median survival was more prominent in the lower risk groups of the WPSS than in the higher-risk groups. Conclusion: In addition to the WPSS, age was found to significantly influence the prognosis of patients with MDS and provided a more individualized prognosis for the patients with MDS. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
17. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer.
- Author
-
Kim, Sung Hyun, Seo, Bo Kyoung, Lee, Juneyoung, Kim, Seok Jin, Cho, Kyu Ran, Lee, Ki Yeol, Je, Bo-Kyung, Kim, Hee Young, Kim, Young-Sik, and Lee, Ju-Han
- Subjects
- *
BREAST cancer , *ULTRASONIC imaging , *TUMOR markers , *PROGNOSIS , *HISTOLOGY - Abstract
Background and purpose. Ultrasound has been used successfully to differentiate benign and malignant breast lesions. The aim of this study was to investigate the correlation between ultrasound and prognostic indicators in breast cancer such as histological type, tumor grade, and biological markers. Materials and methods. Ultrasound findings (shape, margin, orientation, boundary, echo pattern, posterior acoustic feature, and presence of calcifications) of 458 breast cancers were analyzed and correlated with the tumor type, tumor grade, and biological markers by univariate and multivariate logistic regression analyses. The biological markers were estrogen receptor, progesterone receptor, and HER-2/neu. Results. Invasive cancers displayed more frequently an irregular shape, a not parallel orientation, and a hypoechoic or complex echo pattern than carcinoma in situ cases (p<0.05). Poorly differentiated invasive cancers had more frequently not circumscribed margins, an abrupt boundary, and a hypoechoic or complex echo pattern than moderately/well differentiated cancers (p<0.05). Estrogen or progesterone receptor negative cancers more often displayed a hypoechoic or complex echo pattern and HER-2/neu positive cancers had more calcifications (p<0.05). Conclusion. Ultrasound pattern is correlated with tumor type, tumor grade, and biological markers in breast cancers and it may be useful for prediction of prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
18. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy.
- Author
-
Byun, Ja Min, Hong, Junshik, Yoon, Sung-Soo, Koh, Youngil, Ock, Chan-Young, Kim, Tae Min, Lee, Ji Hyun, Kim, Sung-Hyun, Lee, Jeong-Ok, Bang, Soo-Mee, Yhim, Ho-Young, Bae, Sung Hwa, Mun, Yeung-Chul, and Oh, Doyeun
- Subjects
- *
CENTRAL nervous system , *THROMBOEMBOLISM , *DIFFUSE large B-cell lymphomas , *VENOUS thrombosis , *PROGNOSIS , *CEREBRAL embolism & thrombosis , *CANCER prognosis - Abstract
Venous thromboembolism (VTE) may lead to diminished quality of life and ultimately worse prognosis in cancer patients, but there is limited data on the incidence, risk factors and mortality impact of VTE in Asian primary central nervous system lymphoma (PCNSL) patients. To report the incidence, risk factors and mortality impact of VTE in Asian PCNSL patients. From 7 academic centers in Korea, 235 newly diagnosed PCNSL patients undergoing chemotherapy were retrospectively identified during period of January 2004 to September 2018. All patients but 12 (6 T-cell, 6 other B-cell) had diffuse large B-cell lymphoma. During the median follow-up of 21 months, 33 patient (14.0%) developed VTE. Of the VTE events, 11 (33.3%) were deep vein thrombosis (DVT), 15 (45.5%) were pulmonary thromboembolism (PTE), and 7 (21.2%) were DVT with PTE. The median time to VTE was 2 months and the one-year actuarial incidence was 11.7%. On multivariate analysis, ECOG performance ≥2, age >60 years, female sex, and Hb <10 g/dL were independently associated with VTE. The patients with VTE were associated with shorter disease specific survival (P = 0.046) and overall survival (P = 0.022). Overall, the incidence of VTE in Asian PCNSL seems to be lower compared to Western population. As VTE development is associated with overall survival and indicative of relapse, careful close monitoring is warranted. • The VTE incidence is lower in Asian PCNSL patients compared to non-Asians. • The VTE development in PCNSL is associated with reduced survival. • Poor performance, old age, female sex, and Hb <10 g/dL are associated with VTE. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.